Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 853-858

  Chahbouni, Mariam ^a,b   Escames, Germaine ^a,b   López, Luis C ^a,b   Sevilla, Belén ^c   Doerrier, Carolina ^a,b   Muñoz Hoyos, Antonio ^c   Molina Carballo, Antonio ^c   Acuña Castroviejo, Darío ^a,b,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Erythrocytes; Melatonin therapy; Muscular dystrophy; Oxidative stress

Indexed keywords

GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; INDOLEAMINE; PREDNISONE; SUPEROXIDE DISMUTASE;

ADOLESCENT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; ERYTHROCYTE; EVENING DOSAGE; HUMAN; HUMAN CELL; MORNING DOSAGE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; ENZYME STABILITY; ERYTHROCYTES; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HUMANS; MELATONIN; MUSCULAR DYSTROPHY, DUCHENNE; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE;

EID: 79958861173     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.001     Document Type: Article

References (62)

1. Bonilla E., Samitt C.E., Miranda A.F., Hays A.P., Salviati G., DiMauro S., et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988, 54:447-452.
2. Deconinck N., Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypothesis. Pediatr Neurol 2007, 36:1-7.
3. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:239-291.
4. Spence H.J., Chen F.-J., Winder S.J. Muscular dystrophies, the cytoskeleton and cell adhesion. Bioessays 2002, 24:542-552.
5. Brown R.H. Free radicals, programmed death and muscular dystrophy. Curr Opin Neurol 1995, 8:373-378.
6. Tidball J.G., Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007, 102:1677-1686.
7. Reid M.B., Durham W.J. Generation of reactive oxygen and nitrogen species in contracting skeletal muscle: potential impact on aging. Ann NY Acad Sci 2002, 959:108-116.
8. Haycock J.W., MacNeil S., Jones P., Harris J.B., Mantle D. Oxidative damage to muscle protein in Duchenne muscular dystrophy. Neuroreport 1996, 8:357-361.
9. Ragusa R.J., Chow C.K., Porter J.D. Oxidative stress as a potential pathogenic mechanism in animal model of Duchenne muscular dystrophy. Neuromuscul Disord 1997, 7:379-380.
10. Rodriguez M.C., Tarnopolsky M.A. Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 2003, 34:1217-1220.
11. Nakae Y., Stoward P.J., Kashiyama T., Shono M., Akagi A., Matsuzaki T., et al. Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice. J Mol Histol 2004, 35:489-499.
12. Messina S., Altavilla D., Aguennouz M., Seminara P., Minutoli L., Monici M.C., et al. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926.
13. Rando T.A., Disatnik M.H., Yu Y., Franco A. Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 1998, 8:14-21.
14. Dudley R.W., Khairallah M., Mohammed S., Lands L. Des Rosiers C, Petrof BJ. Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am J Physiol Regul Integr Comp Physiol 2006, 291:R704-R710.
15. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., et al. l-Arginine decreases inflammation and modulates the nuclear factor-kB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 2008, 172:1509-1519.
16. Jamaluddin M., Wang S., Boldogh I., Tian B., Brasier A.R. TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 2007, 19:1419-1433.
17. Phillips L., Toledo A.H., Lopez-Neblina F., Anaya-Prado R., Toledo-Pereyra L.H. Nitric oxide mechanism of protection in ischemia and reperfusion injury. J Invest Surg 2009, 22:46-55.
18. Wink D.A., Hanbauer I., Krishna M.C., DeGraff W., Gamson J., Mitchell J.B. Nitric oxide protects against cellular damage and cytotoxity from reactive oxygen species. Proc Natl Acad Sci USA 1993, 90:9813-9817.
19. Chahbouni M., Escames G., Venegas C., Sevilla B., García J.A., López L.C., et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010, 48:282-289.
20. Escames G., Acuña-Castroviejo D., López L.C., Tan D.X., Maldonado M.D., Sánchez-Hidalgo M., et al. Pharmacological utility of melatonin in the treatment of septic shock. J Pharm Pharmacol 2006, 58:1153-1165.
21. Ferretti G., Tangorra A., Curatola G. Effects of intramembrane particle aggregation on erythrocyte membrane fluidity: an electron spin resonance study in normal and in dystrophic subjects. Exp Cell Res 1990, 191:14-21.
22. Piperi C., Papapanagiotou A., Kalofoutis C., Zisaki K., Michalaki V., Tziraki A., et al. Altered long chain fatty acids composition in Duchenne muscular dystrophy erythrocytes. In Vivo 2004, 18:799-802.
23. Hissin P.J., Russel H. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976, 74:214-226.
24. Jaskot R.H., Charlet E.G., Grose E.C., Grady M.A., Roycroft J.H. An automatic analysis of glutathione peroxidasa, glutathione-S-transferase, and reductase activity in animal tissue. J Anal Toxicol 1983, 7:86-88.
25. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974, 249:7130-7139.
26. Misra H.P., Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
27. Disatnik M.H., Dhawan J., Yu Y., Beal M.F., Whirl M.M., Franco A.A., et al. Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. J Neurol Sci 1998, 161:77-84.
28. Passaquin A., Renard M., Kay L., Challet C., Mokhtarian A., Wallimann T., et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002, 12:174-182.
29. Lee R., Britz-McKibbin P. Differential rates of glutathione oxidation for assessment of cellular redox status and antioxidant capacity by capillary electrophoresis-mass spectrometry: an elusive biomarker of oxidative stress. Anal Chem 2009, 81:7047-7056.
30. López-Mirabal R., Winther J.R. Redox characteristics of the eukaryotic cytosol. Biochim Biophys Acta 2008, 1783:629-640.
31. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001, 30:1191-1212.
32. Prutz W.A. Chemical repair in irradiated DNA siolutions containing thiol and/or disulphides. Further evidence for disulphide radical anions acting as electron donors. Int J Radiat Biol 1989, 56:21-33.
33. Kar N.C., Pearson C.M. Catalase, superoxide dismutase, glutathione reductase and thiobarbituric acidreactive products in normal and dystrophic human muscle. Clin Chim Acta 1979, 94:277-280.
34. Armstrong R.N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 1997, 10:2-18.
35. Hayes J.D., McLellan L.I. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999, 31:273-300.
36. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
37. Faist V., Koenig J., Hoeger H., Elmadfa I. Mitochondrial oxygen consumption, lipid peroxidation and antioxidant enzyme systems in skeletal muscle of senile dystrophic mice. Pflugers Arch 1998, 437:168-171.
38. Toscano A., Messina S., Campo G.M., Di Leo R., Musumeci O., Rodolico C., et al. Oxidative stress in myotonic dystrophy type 1. Free Radic Res 2005, 39:771-776.
39. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008, 65:2001-2018.
40. Tan D.X., Manchester L.C., Reiter R.J., Qi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000, 9:137-159.
41. Reiter R.J., Paredes S.D., Manchester L.C., Tan D.X. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009, 44:175-200.
42. Tan D.-X., Chen L.-D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993, 1:57-60.
43. Hardeland R., Tan D.X., Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009, 47:109-126.
44. Schaefer M., Hardeland R. The melatonin metabolite N1-acetyl-5-methoxykynuramine is a potent singlet oxygen scavenger. J Pineal Res 2009, 46:49-52.
45. Antolín I., Rodríguez C., Saínz R.M., Mayo J.C., Uría H., Kotler M.L., et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996, 10:882-890.
46. Escames G., López L.C., Tapias V., Utrilla P., Reiter R.J., Hitos A.B., et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006, 40:71-78.
47. Rodríguez M.I., Carretero M., Escames G., López L.C., Maldonado M.D., Tan D.X., et al. Chronic melatonin treatment prevents age-dependent cardiac mitochondrial dysfunction in senescence-accelerated mice. Free Rad Res 2007, 41:15-24.
48. Forman K., Vara E., García C., Kireev R., Cuesta S., Acuña-Castroviejo D., et al. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J Pineal Res 2010, 49:312-320.
49. Veneroso C., Tuñón M.J., González-Gallego J., Collado P.S. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 2009, 47:184-191.
50. López A., García J.A., Escames G., Venegas C., Ortiz F., López L.C., et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 2009;Mar, 46:188-198.
51. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggiero F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010, 48:297-310.
52. Hibaoui Y., Roulet E., Ruegg U.T. Melatonin prevents oxidative stress-mediated mitochondrial permeability transition and death in skeletal muscle cells. J Pineal Res 2009, 47:238-252.
53. Acuña Castroviejo D., López L.C., Escames G., López A., García J.A., Reiter R.J. Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem 2011, 11:221-240.
54. Li Z.R., Reiter R.J., Fujimori O., Oh C.S., Duan Y.P. Cataractogenesis and lipid peroxidation in newborn rats treated with buthionine sulfoximine: preventive actions of melatonin. J Pineal Res 1997, 22:117-123.
55. Urata Y., Honma S., Goto S., Todoroki S., Iida T., Cho S., et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999, 27:838-847.
56. Martín M., Macías M., Escames G., León J., Acuña-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000, 14:1677-1679.
57. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
58. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:177-189.
59. Kinali M., Arechavala-Gomeza V., Feng L., Cirak S., Hunt D., Adkin C., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8:918-928.
60. Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010, 20:355-362. Meeting Steering Committee and TREAT-NMD Network. 2010.
61. Farini A., Razini P., Erratico S., Torrente Y., Meregalli M. Cell based therapy for Duchenne muscular dystrophy. J Cell Physiol 2009, 221:526-534.
62. Gitto E., Aversa S., Reiter R.J., Barberi I., Pellegrino S. Update on the use of melatonin in pediatrics. J Pineal Res 2011, 50:21-28.